Hormone Therapy Clinical Trials
Open to recruitment
POETIC: POETIC is a randomised phase III multicentre trial in postmenopausal women with ER/PgR positive invasive breast cancer.
In active follow-up
IES: The Intergroup Exemestane Study (IES) is a randomised double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years, comparing subsequent adjuvant exemestane treatment with further tamoxifen to complete a total of 5 years endocrine therapy.
Intercontinental: Intercontinental is an international phase III randomised trial comparing intermittent versus continuous androgen suppression for patients with prostate-specific-antigen progression in the clinical absence of distant metastases following radiotherapy for prostate cancer.
SOFT: SOFT is a phase III, randomised, multicentre study evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for pre-menopausal women with endocrine responsive breast cancer.
TEXT: A phase III trial evaluating the role of exemestane plus GnRH analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer.
UK HRT: National randomised trial of Hormone Replacement Therapy (HRT) in women with a history of early stage breast cancer.